Biotech Values

[ThomasS]

MNTA: "Does the FDA's acceptance of the application as a 505(j) shed any light on how they view MNTA's technology? There are analysts out defending TEVA stating that generic Copaxone will likely fall under the new biologics legislation..."

I would characterize it as a "positive," wouldn't you? Of course the analysts will defend whatever position benefits their clients, although (as MNTA has learned via the Lovenox application) anything is possible in such gray areas of the FDA.